GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinogen Medical Ltd (OTCPK:ATGGF) » Definitions » Valuation Rank

ATGGF (Actinogen Medical) Valuation Rank


View and export this data going back to 2018. Start your Free Trial

What is Actinogen Medical Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Actinogen Medical Valuation Rank Related Terms

Thank you for viewing the detailed overview of Actinogen Medical's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Actinogen Medical Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinogen Medical Ltd (OTCPK:ATGGF) » Definitions » Valuation Rank
Comparable Companies
ASX:PIQ ASX:AGN ASX:NUZ ASX:RCE ASX:TYP ASX:RAD ASX:ADO ASX:SPL ASX:PAR ASX:EZZ VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
3AC:Germany ACW:Australia
Address
109 Pitt Street, Level 9, Suite 901, Sydney, NSW, AUS, 2000
Website
https://www.actinogen.com.au
Actinogen Medical Ltd is a biotechnology company. The company develops drugs for Alzheimer's disease and the cognitive decline associated with other neurological diseases. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.